Clinical trials: Influenza Virus Infection
Influenza
Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age
This study proposes to enroll 50 young infants, ages 10 to 22 weeks. Each of the fifty infants will receive two 0.25mL doses of preservative-free Fluzone®, given a minimum of 28 days apart but no more than 42 days apart.
- Trial name
- NCT00231920
- Testing
- Fluzone
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Vaccines
Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness (VE), whether prior vaccination has any…
- Trial name
- FluSHED-2 (NCT03735147)
- Testing
- Live attenuated influenza vaccine (LAIV)
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza
Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities
The purpose of this research is to study side effects and safety of a new H5N1 flu (bird flu) vaccine and to look at how well people's immune systems make antibodies to fight infection after they get the vaccine.
- Trial name
- NCT00311649
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer
A Study of a Live Intranasal Influenza Vaccine in Children With Cancer
Eligible research subjects will be randomized to receive either FluMist or inactivated influenza vaccine then stratified by age and necessity to receive either one or two immunizations.
- Trial name
- FMRESP (NCT00906750)
- Testing
- FluMist, Inactivated influenza vaccine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- St. Jude Children's Research Hospital
Influenza
Influenza Reminder Text-Messaging
Through a large, population-level quality improvement effort within the Children's Hospital of Philadelphia Care Network, we will evaluate text message reminders on flu vaccination rates for both patients with and without a…
- Trial name
- NCT06587984
- Testing
- Text message reminder
- Where
- United States
- Volunteers
- 228,361 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Immune Response
Immune Responses Induced by Different Licensed Influenza Vaccines
The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.
- Trial name
- NCT00902278
- Testing
- Flulaval, Fluvirin, Fluzone
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Influenza
Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine
Prospective study to evaluate the safety and immunogenicity of Butantan Influenza seasonal vaccine.
- Trial name
- FLU-01-IB (NCT02819115)
- Testing
- Butantan Fragmented Inactivated Trivalent Influenza Vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Influenza
Higher Dose Intradermal H5 Vaccine
This study will compare the influenza A/H5N1 virus vaccine given by injection in the muscle versus injection in the skin in healthy adults.
- Trial name
- NCT00439335
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine
This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
- Trial name
- NCT07291635
- Testing
- Recombinant Influenza vaccine candidate, Commercial Influenza vaccine
- Where
- 7 sites in Canada
- Volunteers
- 728 people, healthy volunteers welcome
- Sponsor
- Aramis Biotechnologies Inc.
Upper Respiratory Disease, Influenza
Immune Defense Protein Impact On Respiratory Immune Outcomes
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season.
- Conditions
- Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
- Trial name
- NCT07431840
- Testing
- Immune Defense Protein 50mg Dose, IDP 200mg Dose
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Quantec Ltd
Influenza
A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults
This study is designed to test the immunogenicity and reactogenicity of the FluarixTM/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2009-2010 season.
- Trial name
- NCT00920374
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 5 sites in Germany
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Heterosubtypic Immune Responses to Influenza in Older People
Vaccination is the principal means of combating epidemic and pandemic influenza. As vaccines induce relatively strain-specific and short-lived antibody responses, annual immunisation with regularly updated vaccine is recommended…
- Trial name
- NCT00798343
- Testing
- Seasonal vaccine, H5 vaccine
- Where
- United Kingdom
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Influenza, Acute Respiratory Infection
FluSAFE: Flu SMS Alerts to Freeze Exposure
Influenza infection results in an estimated 31 million outpatient visits, 55,000 to 974,200 hospitalizations, and 3,000 to 49,000 deaths.
- Conditions
- Influenza, Acute Respiratory Infection, Influenza-like Illness
- Trial name
- NCT03274310
- Testing
- Educational text messages
- Where
- United States
- Volunteers
- 1,918 people, healthy volunteers welcome
- Sponsor
- Columbia University
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Tract Infections
Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)
This trial is taking place in Los Angeles, CA at clinics within the Los Angeles Department of Health clinics. The study design is a comparative effectiveness trial design.
- Trial name
- LADHS (NCT05535777)
- Testing
- Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts
- Where
- 2 sites in United States
- Volunteers
- 246,295 people
- Sponsor
- University of California, Los Angeles
Influenza and Acute Respiratory Viral Infections
Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children
The purpose of this study is: To obtain additional data on therapeutic efficacy of Anaferon for children in the treatment of influenza and acute respiratory viral infections in children
- Trial name
- NCT02072174
- Testing
- Anaferon for Children
- Where
- 27 sites in Belarus, Russia and 1 more
- Volunteers
- 569 people
- Sponsor
- Materia Medica Holding
Influenza
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
The primary objectives of the study are: To describe the safety profile of the different quadrivalent recombinant influenza vaccine (RIV) formulations.
- Trial name
- FBP00001 (NCT04144179)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of a Pandemic Influenza Vaccine in Elderly Participants
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic.
- Trial name
- NCT00376402
- Testing
- H5N1 Pandemic Influenza Vaccine
- Where
- 2 sites in Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Seqirus
Vaccine Response
Probiotics and Influenza Vaccination Response
Assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.
- Trial name
- VERB (NCT05690373)
- Testing
- Probiotic effect on influenza vaccine response
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.